Drugs / LMN-401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06556940 | Dec 2024 → Oct 2025 overdue | diarrhea 13 | Lumen Bioscience, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMN-401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06556940 ↗ |
| Route | Oral | “Orally delivered tablets and capsules” NCT06556940 ↗ |